Halozyme Therapeutics expecting $300M revenue from milestone payments frome Enhanze partnership programs

The a biotechnology maker of novel oncology and drug-delivery therapies, Halozyme Therapeutics, expects three Enhanze programs to be in phase 3 studies and to have nine active phase 1 programs in addition to its three currently marketed products, by the end of 2019, the company said in an update.

Read more